RxDoctor Payments Data

Jennifer Becker, MD

Rheumatology · Spartanburg, SCNPI 1912129354

Payments from drug & device makers

$396in general payments, 2019–2025

Across 11 payments — averaging $35.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$122
  • AbbVie$97
  • Amgen$70
  • Pfizer$58
  • Johnson & Johnson$30
  • Sobi, Inc$19

What the payments were for

  • Food & beverage$37795%
  • Education$195%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC6$122
AbbVie1$97
Amgen1$70
Pfizer1$58
Johnson & Johnson1$30
Sobi, Inc1$19

How this compares

$396 in reported general payments places this provider in the 15th percentile of 123 rheumatology providers in South Carolina.

See all rheumatology providers in South Carolina

Medicare billing

Part B allowed, 2024
$137,827
Medicare patients
401
Services billed
1,221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept125$977,200
Orencia ClickjectAbatacept46$322,141
Humira(Cf)Adalimumab27$291,996
Humira(Cf) PenAdalimumab35$251,693
EnbrelEtanercept33$247,515
Xeljanz XrTofacitinib Citrate26$215,563
Actemra ActpenTocilizumab27$127,841
Cosentyx Sensoready PenSecukinumab17$126,595
Humira PenAdalimumab14$122,642
Taltz AutoinjectorIxekizumab16$119,230
Cosentyx Sensoready (2 Pens)Secukinumab13$95,096
XeljanzTofacitinib Citrate15$81,494
SimponiGolimumab13$81,100
HumiraAdalimumab11$76,638
BenlystaBelimumab13$62,854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf), Humira$97$368,63538 claims
AmgenEnbrel$70$247,51533 claims
PfizerXeljanz$58$81,49415 claims
Johnson & JohnsonSimponi$30$81,10013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 123 rheumatology providers in South Carolina.

Other rheumatology in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →